News & Updates

New drug applications approved by US FDA as of 01-15 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Individuals who have received mpox vaccination or have been previously exposed to mpox infection, which is used to be called monkeypox, appear to be better protected against severe disease from a subsequent infection, as shown in a study.

Comparisons of atypical antipsychotics and haloperidol reveal similar rates of in-hospital adverse clinical events in older patients with postoperative delirium who have taken an oral low-to-moderate dose antipsychotic drug, a study has shown.

Use of ferric carboxymaltose in patients who have heart failure with a reduced ejection fraction and iron deficiency appears to yield only numerical improvements the hierarchical composite of death, hospitalizations for heart failure, or 6-minute walk distance as compared with placebo, according to data from the HEART-FID trial.

It remains uncertain whether morning or bedtime dosing of antihypertensive drugs is better than the other in terms of efficacy, but the latter appears to significantly reduce the incidence of myocardial infarction (MI), suggests a study.

The covalent KRAS G12C inhibitor divarasib shows durable antitumour activity in patients harbouring KRAS G12C-positive tumours, with mostly low-grade adverse events, as shown in the phase I GO42144 study.